Clinical Trials Directory

Trials / Unknown

UnknownNCT04205058

Coffee After Pancreatic Surgery

Coffee After Pancreatic Surgery - a Randomised, Single Blinded, Placebo-controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
199 (estimated)
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Postoperative ileus is a common complication after major abdominal surgery. A positive effect of coffee to bowel movement has been described after colorectal and gynecologic interventions. The objective of this randomised controlled trial is to investigate whether the implementation of a fast track protocol with early coffee consumption accelerates the recovery of bowel function after pancreaticoduodenectomy.

Detailed description

Postoperative ileus (POI) is a common disorder after major abdominal surgery, affecting up to 40% of patients undergoing laparotomy. POI is described as the time between surgery and the first passage of flatus and/or stool and tolerance of oral diet. It could be recognised as postoperative complication when is defined as two or more of nausea/vomiting, inability to tolerate oral diet over 24 h, absence of flatus over 24 h, abdominal distention and radiologic confirmation on or after day 4 postoperatively without prior resolution. Multimodal approaches have been described to treat POI; among them, the early consumption of coffee showed a substantial benefit after colorectal and gynecologic surgery. The objective of this randomised placebo-controlled trial is to investigate whether early coffee consumption can accelerate the recovery of bowel function after open pancreaticoduodenectomy.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTStandard coffeeOne 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
DIETARY_SUPPLEMENTCaffeine-free coffeeOne 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
DIETARY_SUPPLEMENTDrinking waterOne 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

Timeline

Start date
2019-09-05
Primary completion
2021-12-05
Completion
2021-12-05
First posted
2019-12-19
Last updated
2019-12-19

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT04205058. Inclusion in this directory is not an endorsement.